Syndax Pharmaceuticals Inc Market Cap ($1.17 Billion)
Market Cap & Net Worth: Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc market cap. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has a market capitalization of $1.17 Billion ($1.17 Billion) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7967 globally and #2387 in its home market, demonstrating a -2.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syndax Pharmaceuticals Inc's stock price $13.10 by its total outstanding shares 89297086 (89.30 Million). Also see Syndax Pharmaceuticals Inc (SNDX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Syndax Pharmaceuticals Inc Market Cap History (2016–2026)
Syndax Pharmaceuticals Inc market cap history from 2016 to 2026. Data shows growth from $640.26 Million to $1.17 Billion (0.82% CAGR). Check SNDX stock price for real-time trading data and today's change.
Index Memberships
Syndax Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.04% | #230 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #880 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.06% | #133 of 263 |
Weight: Syndax Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Syndax Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syndax Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Syndax Pharmaceuticals Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
10.89x
Syndax Pharmaceuticals Inc's market cap is 10.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $640.26 Million | $1.22 Million | -$44.47 Million | 524.80x | N/A |
| 2017 | $782.24 Million | $2.11 Million | -$60.80 Million | 371.08x | N/A |
| 2018 | $397.37 Million | $1.52 Million | -$73.96 Million | 261.95x | N/A |
| 2019 | $784.03 Million | $1.52 Million | -$55.95 Million | 516.83x | N/A |
| 2020 | $1.99 Billion | $1.52 Million | -$73.07 Million | 1309.14x | N/A |
| 2021 | $1.95 Billion | $139.71 Million | $24.93 Million | 13.99x | 78.42x |
| 2022 | $2.27 Billion | $126.58 Million | -$143.75 Million | 17.95x | N/A |
| 2024 | $1.18 Billion | $23.68 Million | -$318.76 Million | 49.85x | N/A |
| 2025 | $1.88 Billion | $172.35 Million | -$285.42 Million | 10.89x | N/A |
Competitor Companies of SNDX by Market Capitalization
Companies near Syndax Pharmaceuticals Inc in the global market cap rankings as of November 3, 2026. Also see balance sheet size of Syndax Pharmaceuticals Inc for a full breakdown of the balance sheet.
Key companies related to Syndax Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Syndax Pharmaceuticals Inc (2016–2026)
Market capitalization of Syndax Pharmaceuticals Inc from 2016 to today. Between 2016 and today, Syndax Pharmaceuticals Inc's market cap moved from $640.26 Million to $ 1.17 Billion, with a yearly change of 0.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.17 Billion | -37.65% |
| 2025 | $1.88 Billion | +58.93% |
| 2024 | $1.18 Billion | -38.82% |
| 2023 | $1.93 Billion | -15.09% |
| 2022 | $2.27 Billion | +16.26% |
| 2021 | $1.95 Billion | -1.57% |
| 2020 | $1.99 Billion | +153.30% |
| 2019 | $784.03 Million | +97.30% |
| 2018 | $397.37 Million | -49.20% |
| 2017 | $782.24 Million | +22.18% |
| 2016 | $640.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Syndax Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.17 Billion USD |
| MoneyControl | $1.17 Billion USD |
| MarketWatch | $1.17 Billion USD |
| marketcap.company | $1.17 Billion USD |
| Reuters | $1.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more